MARIANA FAYMAN: Open Payments
NPI 1386745909 · BEVERLY HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,169 in 60 payments from 7 companies in 2025. Trend: 2023 $760 · 2024 $1,229 · 2025 $1,169
Food & beverage: $1,169
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $500 |
| GENZYME CORPORATION | 5 | $209 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 15 | $206 |
| Janssen Biotech, Inc. | 5 | $124 |
| Ardelyx, Inc. | 3 | $56 |
| Celltrion USA Inc. | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
Products named: DUPIXENT, RINVOQ, XIFAXAN, LINZESS, TREMFYA, CREON, IBSRELA, VEGZELMA.
Industry payments across CA — which companies pay providers there.
